234 related articles for article (PubMed ID: 29799292)
21. Adherence to biologics in patients with psoriasis.
Seale L; Cardwell LA; Feldman SR
Expert Rev Clin Immunol; 2018 Feb; 14(2):155-161. PubMed ID: 29327643
[TBL] [Abstract][Full Text] [Related]
22. Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.
Calara PS; Norlin JM; Althin R; Carlsson KS; Schmitt-Egenolf M
BioDrugs; 2016 Apr; 30(2):145-51. PubMed ID: 26883786
[TBL] [Abstract][Full Text] [Related]
23. Patient Adherence to Biologic Agents in Psoriasis.
Hsu DY; Gniadecki R
Dermatology; 2016; 232(3):326-33. PubMed ID: 27093295
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of Phototherapy in the Age of Biologics.
Calzavara-Pinton P; Zanca A; Arisi M; Rossi MT; Zane C; Venturini M; Ortel B
Dermatology; 2018; 234(5-6):166-172. PubMed ID: 30205372
[TBL] [Abstract][Full Text] [Related]
25. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
Sruamsiri R; Iwasaki K; Tang W; Mahlich J
BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
[TBL] [Abstract][Full Text] [Related]
26. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
27. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis.
Li P; Blum MA; Von Feldt J; Hennessy S; Doshi JA
Value Health; 2010; 13(6):805-12. PubMed ID: 21054657
[TBL] [Abstract][Full Text] [Related]
28. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment.
Wu JJ; Lu M; Veverka KA; Smulders M; Papademetriou E; Yu J; Feldman SR
J Dermatolog Treat; 2019 Aug; 30(5):446-453. PubMed ID: 30554541
[No Abstract] [Full Text] [Related]
29. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
[TBL] [Abstract][Full Text] [Related]
30. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
31. Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study.
Alvarez-Madrazo S; Kavanagh K; Siebert S; Semple Y; Godman B; Maciel Almeida A; Acurcio FA; Bennie M
BMJ Open; 2019 Sep; 9(9):e027059. PubMed ID: 31488467
[TBL] [Abstract][Full Text] [Related]
32. Poor adherence to and persistence with biologics in generalized pustular psoriasis: A claim-based study using real-world data from two large US databases.
Feldman SR; Bohn RL; Gao R; Gray S; Walton SE; Déruaz-Luyet A; Wu JJ
JAAD Int; 2024 Jun; 15():78-83. PubMed ID: 38440298
[TBL] [Abstract][Full Text] [Related]
33. Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database.
Noe MH; Shin DB; Doshi JA; Margolis DJ; Gelfand JM
J Drugs Dermatol; 2019 Aug; 18(8):745-750. PubMed ID: 31424706
[TBL] [Abstract][Full Text] [Related]
34. Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England.
Khalid JM; Fox KM; Globe G; Maguire A; Chau D
J Dermatolog Treat; 2014 Feb; 25(1):67-72. PubMed ID: 23336246
[TBL] [Abstract][Full Text] [Related]
35. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
[TBL] [Abstract][Full Text] [Related]
36. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
[TBL] [Abstract][Full Text] [Related]
37. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
38. Adherence and resource use among psoriasis patients treated with biologics.
Aleshaki JS; Cardwell LA; Muse ME; Feldman SR
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):609-617. PubMed ID: 30142007
[TBL] [Abstract][Full Text] [Related]
39. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea.
Shin JO; Shin BS; Bae KN; Shin K; Kim HS; Ko HC; Kim MB; Kim B
Indian J Dermatol Venereol Leprol; 2023; 89(6):928. PubMed ID: 37317715
[TBL] [Abstract][Full Text] [Related]
40. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.
Hägg D; Eriksson M; Sundström A; Schmitt-Egenolf M
PLoS One; 2013; 8(5):e63619. PubMed ID: 23691076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
